Skip to main content
Premium Trial:

Request an Annual Quote

Texas A&M Wins $12.3M Defense Contract

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Institute for Genomic Medicine (TIGM) at Texas A&M University said today that it has won a contract totaling $12.3 million from the US Department of Defense to screen potential targets that can be used to combat biothreats such as viral and bacterial pathogens and toxins.

The funding from the Defense Threat Reduction Agency (DTRA) will be used to develop high-throughput screening measures in mouse stem cells to discover new vaccines and therapies to counter serious biothreats.

Researchers at TIGM plan to screen over 3,500 different genes to find those that enable microbes and toxins to harm cells and tissues. When those candidates are identified, TIGM will use those to develop therapies to be tested in tissues and pre-clinical models, the university said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more